Investors can learn a lot by observing how corporate insiders handle positions in their own companies. There are many reasons insiders may sell shares, such as buying a house, paying for college, or estate planning. Yet, they generally buy shares for only one reason: they believe they will make more money.
Often, one of the largest and best-informed shareholders in any company is the chief executive officer. Let’s see whether Ginkgo Bioworks Holdings Inc. (NYSE: DNA) CEO Jason Kelly has been increasing or decreasing his share count over the past year and whether he knows something we don’t.
What You Need to Know About Ginkgo Bioworks
Ginkgo Bioworks develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. (These 25 American industries are booming.)
The biotechnology company was founded in 2008 and is headquartered in Boston, Massachusetts. That is also home to American Tower Corp. (NYSE: AMT), DraftKings Inc. (NASDAQ: DKNG), and General Electric Co. (NYSE: GE). Competitors of Ginkgo Bioworks include CRISPR Therapeutics AG (NASDAQ: CRSP) and Editas Medicine Inc. (NASDAQ: EDIT). Kelly has been chief executive at Ginkgo Bioworks since he co-founded it in 2008.
The company posted annual revenue of about $315.0 million and has a market capitalization near $2.8 billion. Shares hit a 52-week low of $1.12 last month and were last seen down about 16% year to date but less than 4% lower than a year ago. The Nasdaq’s gain in the past year is more than 40%.
How the CEO at Ginkgo Bioworks Is Trading
One year ago, Kelly owned more than 108.2 million shares, worth over $337.6 million. On last look, he owed more than 88.1 million shares, a stake of more than 4%. The stake was reduced by about 20 million shares, and its value decreased around 67.8% to near $108.6 million as the share price dropped.
| Shares a Year Ago | Shares Today | % Change |
| 108,213,460 | 88,152,333 | −18.54% |
As mentioned, CEO Jason Kelly might have sold shares for many reasons. Is it fair to interpret this reduction as a lack of confidence about a turnaround? The stock is down over 87% since a short seller report in late 2021. Earnings results fell short of expectations in the past few quarters. Only two of eight analysts recommend buying shares. However, they have a consensus price target of $3.08, which indicates they see the stock doubling in the next 12 months.
Additional insiders to watch include the other co-founders: Austin Che (head of strategy), Reshma Shetty (president and chief operating officer), and Barry Canton (chief technology officer). Each has a stake a little larger than Kelly’s.
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
